Publications by authors named "N Kothari"
Nosocomial bloodstream infections with multidrug-resistant microorganisms have become a common health threat in intensive care settings worldwide. Understanding antimicrobial resistance and the outcomes of these infections is crucial for addressing this issue. This study aimed to investigate the burden, antimicrobial resistance, and 28-day outcomes of nosocomial bloodstream infections in the intensive care unit.
View Article and Find Full Text PDFCystic fibrosis (CF) is a hereditary disorder characterized by mutations in the CFTR gene, leading to impaired chloride ion transport and subsequent thickening of mucus in various organs, particularly the lungs. Despite significant progress in CF management, current treatments focus mainly on symptom relief and do not address the underlying genetic defects. Stem cell and gene therapies present promising avenues for tackling CF at its root cause.
View Article and Find Full Text PDFBackground: We compared the modified ROX index and ROX index scores in earlier predictions of high-flow nasal oxygen (HFNO) therapy outcomes in patients with acute respiratory failure.
Methods: We conducted a prospective observational study on 151 acute respiratory failure patients initiated on HFNO therapy. The primary objective of this research was to compare the modified ROX index and ROX index to investigate which score predicted HFNO treatment outcome earlier.
'Effectiveness of various sulbactam-based combination antibiotic therapy in the management of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in a tertiary care Health centre'.
Indian J Med Microbiol
December 2024
Article Synopsis
- * A total of 103 adult patients with CRAB-related VAP were analyzed, comparing outcomes between those treated with dual and triple antibiotic combinations involving sulbactam.
- * Results indicate that the triple therapy (sulbactam, polymyxin B, and minocycline) significantly reduced 28-day mortality and improved other health markers compared to the dual therapy, suggesting it may be a more effective treatment option.
Article Synopsis
- A study was conducted to investigate the effectiveness of mecillinam and pivmecillinam against urinary tract infection (UTI) bacteria in the U.S. from 2017 to 2020, highlighting its potential as a treatment option.
- Mecillinam showed high susceptibility rates (94.9%) among UTI-causing Enterobacterales, especially against extended-spectrum beta-lactamase (ESBL)-positive strains (98.2%).
- The findings support the clinical development of mecillinam as a promising first-line therapy for uncomplicated UTIs, especially when other common antibiotics showed higher resistance rates.